Venture Icebreaker Panel: When Being Selective, Which Engager Biotech Will Investors Provide Financial Backing To?
Time: 11:30 am
day: Conference Day One
Details:
- How is the engager M&A landscape facilitating successful VC exits and what does that mean for future engager biotech investment?
- Based on deal-making in the engager space in recent years, how are investors viewing the investment window for engager assets and platforms in the near future?
- With data readouts from ASCO & AAI, will considerations for investment into engagers change?
- For both venture capital and investing out of public funds, what will drive or inhibit investment in engagers?
- How can engagers remain relevant to investors?
- How are venture capitalists trying to start new engager biotech, manage IP in an evolving geopolitical landscape and diverse sources of capital across different geographies?
